For the past three years, nearly every breakthrough in obesity medicine has traced back to a single class of drugs: GLP-1 receptor agonists like semaglutide and tirzepatide. Now, a phase 2 clinical ...

The Centers for Medicare & Medicaid Services will launch the Medicare GLP-1 Bridge in July 2026, offering some Part D beneficiaries temporary access to GLP-1 drugs for weight loss alongside coverage ...

There is no shortage of headlines about GLP-1 medications. Originally developed to manage blood sugar levels, these medications are now widely known for promoting weight loss. Alongside their rapid ...

The results of this obesity medication are literally eye-popping. A new review of adverse effects reports to the FDA between the years 2017 and 2024 reveals that Ozempic and Wegovy have both been ...

Where do indications for GLP-1 receptor agonists (RAs) currently stand? Experts addressed these questions at the French Nutrition Days 2025 in Lyon, France, with a focus on obesity treatment, ...

Eli Lilly's LLY.N GLP-1 drug tirzepatide yields greater weight loss on average than Novo Nordisk's NOVOb.CO semaglutide, but at a greater expense to muscles and connective tissues, according to a ...

For many years, scientists and doctors have focused on one main idea when it comes to modern weight loss medicines. They ...

Weight loss drugs like GLP-1s are rapidly reshaping how Americans think about appetite, health and food – forcing CPG brands to reconsider everything from formulation to front-of-pack messaging.